Education
About Us
Working with TipRanks
Follow Us
GenSight Biologics (DE:G49N)
:G49N
RESEARCH TOOLSreports
Total Valuation
GenSight Biologics SA has a market cap or net worth of €26.69M. The enterprise value is ―.
Market Cap€26.69M
Enterprise Value―
Share Statistics
GenSight Biologics SA has 130,534,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding130,534,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GenSight Biologics SA’s return on equity (ROE) is 0.52 and return on invested capital (ROIC) is -777.45%.
Return on Equity (ROE)0.52
Return on Assets (ROA)-1.30
Return on Invested Capital (ROIC)-777.45%
Return on Capital Employed (ROCE)1.33
Revenue Per Employee164.06K
Profits Per Employee-875.06K
Employee Count16
Asset Turnover0.24
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of GenSight Biologics SA is -1.85. GenSight Biologics SA’s PEG ratio is -0.03.
PE Ratio-1.85
PS Ratio0.00
PB Ratio-0.97
Price to Fair Value-0.96
Price to FCF-2.41
Price to Operating Cash Flow-2.02
PEG Ratio-0.03
Income Statement
In the last 12 months, GenSight Biologics SA had revenue of 2.63M and earned -14.00M in profits. Earnings per share was -0.15.
Revenue2.63M
Gross Profit2.63M
Operating Income-15.81M
Pretax Income-13.98M
Net Income-14.00M
EBITDA-14.76M
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was -12.94M and capital expenditures 0.00, giving a free cash flow of -12.94M billion.
Operating Cash Flow-12.94M
Free Cash Flow-12.94M
Free Cash Flow per Share-0.10
Dividends & Yields
GenSight Biologics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.23
52-Week Price Change-50.00%
50-Day Moving Average0.20
200-Day Moving Average0.27
Relative Strength Index (RSI)42.79
Average Volume (3m)0.00
Important Dates
GenSight Biologics SA upcoming earnings date is Sep 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 19, 2025
Next Earnings DateSep 19, 2025
Ex-Dividend Date―
Financial Position
GenSight Biologics SA as a current ratio of 0.24, with Debt / Equity ratio of -71.00%
Current Ratio0.24
Quick Ratio0.24
Debt to Market Cap0.70
Net Debt to EBITDA-1.13
Interest Coverage Ratio-10.18
Taxes
In the past 12 months, GenSight Biologics SA has paid 21.00K in taxes.
Income Tax21.00K
Effective Tax Rate>-0.01
Enterprise Valuation
GenSight Biologics SA EV to EBITDA ratio is -2.88, with an EV/FCF ratio of -3.29.
EV to Sales16.19
EV to EBITDA-2.88
EV to Free Cash Flow-3.29
EV to Operating Cash Flow-3.29
Balance Sheet
GenSight Biologics SA has €2.46M in cash and marketable securities with €19.11M in debt, giving a net cash position of €16.65M billion.
Cash & Marketable Securities€2.46M
Total Debt€19.11M
Net Cash€16.65M
Net Cash Per Share€0.13
Tangible Book Value Per Share-€0.28
Margins
Gross margin is 100.00%, with operating margin of -602.40%, and net profit margin of -533.37%.
Gross Margin100.00%
Operating Margin-602.40%
Pretax Margin-532.57%
Net Profit Margin-533.37%
EBITDA Margin-562.10%
EBIT Margin-602.44%
Analyst Forecast
The average price target for GenSight Biologics SA is €0.40, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€0.40
Price Target Upside122.22% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―